COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
Clinical trial NCT04992273 · TERMINATED
Trial details
- NCT number
- NCT04992273
- Sponsor
- Regeneron Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-13
- Primary completion
- 2022-06-01
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.